$CRTX
Cortexyme Inc
PRICE
$2.72 ▲0.369%
Extented Hours
VOLUME
246,930
DAY RANGE
2.65 - 2.78
52 WEEK
2.64 - 121.98
Key Metrics
Market Cap
82.91 M
Beta
1.48
Avg. Volume
407.86 K
Shares Outstanding
30.15 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-04
Next Dividend Date
Company Information
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Website: www.cortexyme.com
HQ: ,
Related News